托伐普坦用于肝硬化腹水合并低钠血症的治疗特点  

作　　者：韩杰[1] 田姗[1] 郝竟琳 陈倩[1] 张静姝[1] 朱姗薇[1] 

机构地区：[1]解放军第302医院,100039

出　　处：《首都食品与医药》2016年第20期60-61,共2页Capital Food Medicine

摘　　要：托伐普坦作为一种新型非肽类选择性AVPV2受体拮抗剂,获美国FDA批准,适用于治疗各种疾病引起的高溶性和等溶性低钠血症,并且是欧洲肝病协会(EASL)治疗肝硬化低钠血症的推荐指导用药。本文从低钠血症以及肝硬化腹水合并低钠血症的分类和成因入手,分析其有效治疗方法,结合托伐普坦的药理特性,证明其快速排出自由水,减轻水钠潴留的优势,值得推广应用于治疗肝硬化腹水患者。Tolvaptan isapproved by the US FDA as a novel non-peptide selective AVPV2 receptor antagonist for the treatment of various diseases such as soluble and insoluble caused by hyponatremia, and European Association For The Study Of The Liver （EASL） recommended it to be guide therapy for liver cirrhosis hyponatremia. This article isbased on the classification and causes of hyponatremia and ascites of cirrhosis with hyponatremia, analyzes effective treatment methods and combined with tolvaptan pharmacological properties, to prove its advantage of rapid discharge of free water and reducing water- sodium retention, Is worth popularizing for the patients with liver cirrhosis.

关 键 词：托伐普坦 肝硬化腹水 低钠血症 

分 类 号：R575.2[医药卫生—消化系统]